HASBROUCK HEIGHTS, N.J., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that two data presentations of the Company's new drug Fexapotide Triflutate will be held at the November meeting of the American Urological Association, New York Section. The November 6 presentations at the New York AUA meeting in Havana will include a podium presentation authored by Ronald Tutrone MD FACS, Baltimore, MD; Mitchell Efros MD FACS, Garden City, NY; Mohammed Bidair MD, San Diego, CA; James Bailen MD FACS, Louisville, KY; Franklin Gaylis MD FACS, San Diego, CA; Barton Wachs MD FACS, Long Beach, CA; Richard Levin MD FACS, Baltimore, MD; Susan Kalota MD FACS, Tucson, AZ; Sheldon Freedman MD FACS, Las Vegas, NV; Barry Shepard MD FACS, Garden City, NY; Jed Kaminetsky MD FACS, New York, NY; Steven Gange MD FACS, Salt Lake City, UT; and Ivan Grunberger MD FACS, Brooklyn, NY. The podium presentation will be presented by Dr. Ivan Grunberger. Dr. Grunberger is the Immediate Past President of the New York Section of the AUA.

A second Symposium presentation and panel discussion will occur on November 6 at the AUA meeting. The Chairperson of the Symposium will be Ronald Tutrone MD FACS of Chesapeake Urology, Baltimore, MD. Panel members for the Symposium will include Dr. Grunberger; Jeffrey Snyder MD FACS, Denver, CO; and Kenneth Goldberg MD FACS, Carrollton, TX.

Further details on the November 6 presentations at the New York AUA Meeting will be provided prior to the meeting.

Dr. Paul Averback, CEO of Nymox said, "The upcoming meetings and presentations at the AUA meeting November 6 will involve highly experienced and well-known BPH investigators who participated in the trials and who will present data and discuss results of the Fexapotide Phase 3 clinical studies. These represent the second and third of many important communication undertakings with the medical communities which are and will be occurring for Fexapotide."

Nymox's lead drug Fexapotide has been in development for over 10 years and has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers throughout the US, and has been found after 7 years of prospective placebo controlled double blind studies of treatment of 995 U.S. men with prostate enlargement to not only show clinically meaningful and durable relief of BPH symptoms, but also to show a major reduction in the incidence of prostate cancer, compared to placebo and compared to the known and expected normal incidence of the disease. The same clinical program has also shown in a long-term blinded placebo crossover group study an 82-95% reduction in the number of these patients who required surgery after they received crossover Fexapotide in the trial, as compared to patients who did not receive Fexapotide but instead received crossover conventional approved BPH treatments (p<.0001).

For more information please contact  info@nymox.com or 800-936-9669.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forwardlooking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2016, and its Quarterly Reports.

Contact:Paul AverbackNymox Pharmaceutical Corporation800-93NYMOX www.nymox.com